<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To determine the risk factors for adverse renal outcome in type 2 diabetic patients who underwent renal biopsy and were followed-up longitudinally </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: We examined 68 consecutive patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> during the period of 1985-1999 who underwent renal biopsy for <z:hpo ids='HP_0000093'>proteinuria</z:hpo> &gt; or =1 g/day, renal involvement (<z:hpo ids='HP_0000093'>proteinuria</z:hpo> or <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e>) at the absence of <z:hpo ids='HP_0000488'>retinopathy</z:hpo>, renal involvement with duration of <z:mp ids='MP_0002055'>diabetes</z:mp> &lt; 5 years, or unexplained <z:hpo ids='HP_0000790'>hematuria</z:hpo> of glomerular origin </plain></SENT>
<SENT sid="2" pm="."><plain>Their clinical features and underlying renal lesion were correlated with the renal outcome after longitudinal follow-up </plain></SENT>
<SENT sid="3" pm="."><plain>Three groups of patients were defined based on their renal pathology: group I consisted of 24 patients (35%) with diabetic <z:hpo ids='HP_0000096'>glomerulosclerosis</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DGS</z:e>) alone, group II consisted of 13 patients (19%) with nondiabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> (NDN) superimposed on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DGS</z:e>, and group III consisted of 31 patients (46%) with NDN alone without evidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DGS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: After a mean follow-up of 123 months from the diagnosis of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (74 months from the time of renal biopsy), univariate analysis showed that risk factors for reaching <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo> (requiring maintenance dialysis, or a serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> [SCr] &gt; or =700 micromol/l) included <z:hpo ids='HP_0000093'>proteinuria</z:hpo> &gt; or = 2g/day (P = 0.0087), SCr &gt;120 micromol/l (P = 0.0005), presence of <z:hpo ids='HP_0000488'>retinopathy</z:hpo> (P &lt; 0.00001) at the time of biopsy, and biopsy showing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DGS</z:e> (groups I and II) (P = 0.035) </plain></SENT>
<SENT sid="5" pm="."><plain>On multivariate analysis, <z:hpo ids='HP_0000488'>retinopathy</z:hpo> was the only independent variable correlated with <z:hpo ids='HP_0003774'>end-stage renal failure</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>This study also showed that the association of <z:hpo ids='HP_0000790'>hematuria</z:hpo> or <z:hpo ids='HP_0000093'>proteinuria</z:hpo> with the absence of <z:hpo ids='HP_0000488'>retinopathy</z:hpo> constitutes the strongest indication for a nondiabetic lesion (positive predictive values of 94%) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> undergoing renal biopsy constitute a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group by their clinical presentations and underlying pathology, but longitudinal studies on the renal outcome of these patients remain limited </plain></SENT>
<SENT sid="8" pm="."><plain>Our study showed that renal biopsy is indicated in selective diabetic patients because of potentially treatable <z:hpo ids='HP_0000112'>nephropathy</z:hpo> and of a better prognosis than <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DGS</z:e> </plain></SENT>
</text></document>